以岭药业入选华夏大健康“2025年度中医药创新典型案例”

Core Insights - The fifth Huaxia Health Industry Development and Rehabilitation Service Conference was held in Beijing, where Yiling Pharmaceutical was recognized for its achievements in traditional Chinese medicine innovation, being selected as a "2025 Annual Traditional Chinese Medicine Innovation Model Case" [1] Group 1: R&D Investment and Achievements - Yiling Pharmaceutical prioritizes R&D as the core driver of its development, with R&D investment reaching 544 million yuan in the first three quarters of 2025, accounting for 9.27% of its operating revenue, leading the industry [3] - Cumulatively, from 2019 to 2024, the company has invested over 5 billion yuan in R&D, establishing a virtuous cycle of "investment-transformation-reinvestment" to produce "Chinese medicine" that aligns with the genetic and physical characteristics of the Chinese population [3] - In 2025, Yiling Pharmaceutical's R&D pipeline has yielded significant results, including the approval of the traditional Chinese medicine Qifang Nasal Congestion Tablets by the National Medical Products Administration, which has also been registered in Macau, marking it as the first registered innovative traditional Chinese medicine in Macau [3] Group 2: Product Development and Market Impact - Four new traditional Chinese medicines, including Qigui Luobitong Tablets and Children's Lianhua Qingwen Granules, are in the application stage, while five others are undergoing clinical research, covering major diseases in respiratory, rheumatology, and neurology fields [3] - Yiling Pharmaceutical holds 17 patented traditional Chinese medicines that address major diseases such as cardiovascular, respiratory, and endocrine disorders, with 11 products included in the national medical insurance catalog and five in the national essential drug catalog, effectively reducing the medication burden on patients [3] Group 3: Evidence-Based Medicine and Global Outreach - The company emphasizes high-standard evidence-based medical research to promote traditional Chinese medicine globally, with its series of studies on vascular event chain interventions attracting international attention, published in top medical journals such as JAMA and Nature Medicine [4] - Yiling Pharmaceutical has initiated over 40 evidence-based medical studies, establishing a research evidence system that integrates traditional Chinese and Western medicine [4] Group 4: Industry Recognition and Innovation - The selection process for the innovation model cases involved extensive research and professional evaluation by hundreds of media outlets, experts, and industry scholars, highlighting representative and exemplary innovation cases across various dimensions, including corporate practices, technology applications, brand building, and cultural stories [4][5] - The release and display of these cases aim to convey a positive industry trend, promote a pragmatic and innovative spirit, and foster the healthy development of enterprises in the health sector [5]